In a JAMA Network Open study, researchers found no evidence of neuroinflammation or blood-brain barrier dysfunction in cerebrospinal fluid markers of individuals with post-COVID-19 condition and neuropsychiatric symptoms compared to controls. The study, which assessed cytokines, chemokines, and neuroinflammation markers, suggests that persistent central nervous system immune activation may not be the primary driver of neurological long COVID symptoms.
Lexicon’s president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
September 21, 2024